AcelRx Pharmaceuticals Inc. (ACRX)
Symbol Info
Listed Symbol ACRX
Name AcelRx Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $2,151,000
Latest Fiscal EPS $-0.81
Price Info
21 Day Moving Average $2.3886
21 Day EMA $2.453210
50 Day Moving Average $2.4562
50 Day EMA $2.463500
200 Day EMA $2.759640
200 Day Moving Average 2.803950
52 Week High $5.05
52 Week Low $1.99
52 Week Change $-32.432400
Alpha 0.000967
Beta 2.1284
Standard Deviation 0.241035
R2 0.092439
Periods 60
Share Information
10 Day Average Volume 845,516
20 Day Average Volume 798,033
30 Day Average Volume 794,121
50 Day Average Volume 923,274
Outstanding Shares 79,435,542
Float Shares 77,493,699
Percent Float 97.56%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 142
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 7,484,302
Institute Holdings Percent 32.400000
Institute Sold Previous 3 Months 2,232,182
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,941,843
Price Change
7 Day Price Change $-0.05
7 Day Percent Change -1.96%
21 Day Price Change $0.1700001
21 Day Percent Change 7.30%
30 Day Price Change $0.2000001
30 Day Percent Change 8.70%
Month To Date Price Change $0.1700
Month To Date Percent 7.30%
90 Day Price Change $0.140000
90 Day Percent Change 5.93%
Quarter To Date $-0.03
Quarter To Date Percent -1.19%
180 Day Price Change $-0.85
180 Day Percent Change -25.37%
200 Day Price Change $-1.33
200 Day Percent Change -34.73%
Year To Date $0.190000
Year To Date Percent 8.23%
Profile
Description AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has one approved product in the U.S., DSUVIA (sufentanil sublingual tablet) known as DZUVEO in Europe indicated for the management of acute pain, severe enough to require an opioid analgesic for adult patients and one product candidate, Zalviso (sufentanil sublingual tablet system, SST system being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.
Details
Issue Type CS
Market Cap $198,588,855
Sec Type EQS
Auditor OUM & Co. LLP
Total Shares Outstanding 79,435,542
CEO Vincent J. Angotti
Employees 90
Last Audit UQ
Classification
CIK 0001427925
Industry Medical Devices
Sector Healthcare
NAICS Surgical and Medical Instrument Manufacturing(339112)
Info
Address 351 Galveston Drive
Redwood City, CA 94063
Website http://www.acelrx.com
Facisimile +1 650 216-6500
Telephone +1 650 216-3500
Email investors@acelrx.com
Key Ratios
Profitability
EBIT Margin -2,007.9
EBITDA Margin -1,961.7
Pre-Tax Profit Margin -771.2
Profit Margin Cont -
Gross Margin -134.7
Profit Margin TOT -
Income Statements
Revenue $2,196,000
Revenue Per Share $0.0276
Revenue 3 Years $-52.83
Revenue 5 Years $-28.92
Valuation Measures
PE Ratio -
Enterprise Value $153,286,674
Price To Sales 90.432080
Price To Free Cash -5
PE High Last 5 Years -
Price To Book 71.8
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -11.7
Financial Strength
Total Debt To Equity -
Int Coverage -6.3
Current Ratio 11.7
Leverage Ratio -7.2
Quick Ratio 11.1
Long Term Debt To Capital -
Assets
Receivables Turnover 2.2
Invoice Turnover 3.00
Assets Turnover -
Management Effectiveness
Return Assets -57.38
Return On Equity 154.50
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACRX
AcelRX Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.